Skip to main content

Advertisement

Table 1 Sensitivity of commercial CCP2 test and noncommercial CFFCP enzyme-linked immunosorbent assays in different rheumatoid arthritis populations and control groups

From: Diagnostic and prognostic value of antibodies against chimeric fibrin/filaggrin citrullinated synthetic peptides in rheumatoid arthritis

Population n CFFCP1 CFFCP2 CFFCP3 CCP2
Rheumatoid arthritis 322 232 (72%) 251 (78%) 230 (71.4%) 238 (73.9%)
   RF+ 226 188 (83.2%) 199 (88.1%) 192 (85%) 199 (88.1%)
   RF-a 95 43 (45.3%) 52 (54.7%) 38 (40%) 39 (41.1%)
   Early 134 102 (76.1%) 104 (77.6%) 99 (73.9%) 99 (73.9%)
   Anti-TNF-α treatment 78 56 (71.8%) 62 (79.5%) 61 (78.2%) 62 (79.5%)
Healthy blood donors 307 6 (2%) 6 (2%) 6 (2%) 6 (2%)
Systemic lupus erythematosus 119 11 (9.2%) 11 (9.2%) 9 (7.6%) 9 (7.6%)
Psoriatic arthritis 133 6 (4.5%) 13 (9.8%) 2 (1.5%) 4 (3%)
Hepatitis C virus infection 84 12 (14.3%) 2 (2.4%) 2 (2.4%) 1 (1.2%)
  1. aP < 0.0001 for all autoantibodies in comparison with RF+ rheumatoid arthritis. In one RA patient, RF status was not available. RF = rheumatoid factor; TNF = tumor necrosis factor.